Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
– Phase 2 study in cholestatic liver diseases, focused on PBC and PSC, anticipated to initiate in Q1 2027 –– Builds on completed Phase 1a study and ongoing development in HDV – SOUTH SAN FRANCISCO,...
-
Dublin, May 21, 2026 (GLOBE NEWSWIRE) -- The "Emerging Drugs: Global Markets" report has been added to ResearchAndMarkets.com's offering.The report provides an overview of the global emerging drugs...
-
ORION CORPORATION PRESS RELEASE 21 MAY 2026 at 10:30 EEST Orion Pharma to present its first clinical data from Phase 1/2 TEADES trial of TEAD inhibitor ODM-212 at the 2026 ASCO® Annual Meeting First...
-
ORION OYJ LEHDISTÖTIEDOTE 21.5.2026 KLO 10.30 Orion Pharma julkistaa ensimmäisiä kliinisiä tuloksia Faasi 1/2 TEADES-tutkimuksesta ODM-212-molekyylillä (TEAD-estäjä) 2026...
-
Dublin, May 20, 2026 (GLOBE NEWSWIRE) -- The "Medical Foods Market Size, Share & Trends Analysis Report by Route of Administration, Product, Application, Sales Channel, Module, Region, and...
-
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement...
-
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés...
-
AI Products Showcase
-
Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "Project Management for Pharma Professionals (July 2nd - July 3rd, 2026)" training has been added to ResearchAndMarkets.com's offering.This course has...
-
Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "EU Proposed Pharmaceutical Legislation Changes (July 1, 2026)" training has been added to ResearchAndMarkets.com's offering. The course is designed...